Drugs / BVL-GSK098
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04654143 | Dec 2020 → May 2022 | — | BioVersys AG | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05473195 | Dec 2022 → Apr 2024 | primary pulmonary tuberculosis | TASK Applied Science | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BVL-GSK098 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04654143 ↗ |
| Known as | alpibectir | “First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug.” PMID 38656557 ↗ Jun 2024 |
| Route | Oral | “alpibectir administered as single and multiple oral doses in healthy volunteers” PMID 38656557 ↗ Jun 2024 |